

Cat No. 80-Z03

Dovitinib


10 mg



For research purposes only

Dovitinib is a small molecule receptor tyrosine kinase inhibitor. It potently inhibits receptor tyrosine kinases including FLT3, c-KIT, CSF-1R/c-fms, FGFR1, FGFR3, VEGFR1/Flt1, VEGFR2/Flk1, VEGFR3/Flt4, PDGFR β , and PDGFR α . Dovitinib shows both antitumor and antiangiogenic activities in vivo. It has also been used as an effective treatment in xenograft mouse models of FGFR3 multiple myeloma (MM).

TECHNICAL INFORMATION



STORAGE AND HANDLING

Storage: Store at 4°C and protected from light. Following reconstitution, store aliquots at -20°C.

Stability: Stock solutions stable at -20°C for up to 2 years.

Shipping Conditions: Shipped at room temperature.

PRODUCT USE

Soluble in DMSO at 25 mg/ml. If precipitate is observed, vortex for 5 minutes. For most cells, the maximum tolerance to DMSO is less than 0.5%.

Other Names: CHIR-258, TKI-258

Chemical Formula: C₂₁H₂₁FN₆O•C₃H₆O₃

CAS Number: 692737-80-7

Molecular Weight: 482.51

Purity: >98%

Appearance: a crystalline solid

Solubility: DMSO

REFERENCES

1. Chase et al. (2007) Activity of TKI258 against primary cells and cell lines with FGFR1-fusion genes associated with the 8p11 myeloproliferative syndrome. *Blood*. 110(10):3729-34.
2. Trudel et al. (2005) CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma. *Blood*. 105(7):2491-8.
3. Azab et al. (2011) FGFR3 is overexpressed waldenstrom macroglobulinemia and its inhibition by Dovitinib induces apoptosis and overcomes stroma-induced proliferation. *Clin Cancer Res*. 17(13):4389-99.